The influencing factors of abnormal liver function in patients with COVID-19 and its dynamic changes in different drug treatments

doi:10.3969/j.issn.1006-7795.2022.03.017

Abstract

Abstract: Objective To analyze the influencing factors of abnormal liver function in patients with COVID-19 and the dynamic changes of liver function during hospitalization with different drug treatments. Methods A total of 615 COVID-19 patients were enrolled in this study. According to the baseline liver function, they were divided into two groups: abnormal liver function (225 cases) and normal liver function (390 cases).Liver function was dynamically monitored and Logistic regression analysis was used to screen for independent risk factors affecting abnormal liver function. The effects of lopinavir/ritonavir, faveravir, chloroquine phosphate, antibiotics and Yindan Jiedu Granules (YDJDG) on liver function were evaluated. Results The risk factors for abnormal liver function included age, days from onset to admission, C-reactive protein and D-dimer. The severe group showed significantly higher baseline alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels and lower serum albumin (ALB) levels than the non-severe group. A total of 179 patients developed abnormal liver function during hospitalization. On day 7, the ALT and AST levels in the antiviral group were significantly lower than those in the non-antiviral group (P=0.020 and P=0.033). Conclusion Patients with abnormal liver function are at higher risk of progressing to severe COVID-19. After admission, lopinavir/ritonavir and chloroquine phosphate significantly reduced ALT and AST levels. In this study, no obvious damage to the liver was found from the use of antiviral drugs, antibiotics or YDJDG.

Key words: SARS-CoV-2, abnormal liver function, liver injury, severe, antiviral drugs, antibiotics, Yindan Jiedu Granules

CLC Number:

R563.1

Liu Yao, Feng Ying, Ren Jie, Wang Xianbo. The influencing factors of abnormal liver function in patients with COVID-19 and its dynamic changes in different drug treatments[J]. Journal of Capital Medical University, 2022, 43(3): 433-439.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/10.3969/j.issn.1006-7795.2022.03.017

https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/Y2022/V43/I3/433

References

[1] Fox S E, Akmatbekov A, Harbert J L, et al. Pulmonary and cardiac pathology in African American patients with COVID-19: an autopsy series from New Orleans[J]. Lancet Respir Med, 2020, 8(7): 681-686.
[2] Varga Z, Flammer A J, Steiger P, et al. Endothelial cell infection and endotheliitis in COVID-19[J]. Lancet, 2020, 395(10234): 1417-1418.
[3] Ackermann M, Verleden S E, Kuehnel M, et al. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in COVID-19[J]. N Engl J Med, 2020, 383(2): 120-128.
[4] Barton L M, Duval E J, Stroberg E, et al. COVID-19 autopsies, Oklahoma, USA[J]. Am J Clin Pathol, 2020, 153(6): 725-733.
[5] Shi S B, Qin M, Shen B, et al. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China[J]. JAMA Cardiol, 2020, 5(7): 802-810.
[6] Guo T, Fan Y Z, Chen M, et al. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19)[J]. JAMA Cardiol, 2020, 5(7): 811-818.
[7] Ni W T, Yang X W, Liu J, et al. Acute myocardial injury at hospital admission is associated with all-cause mortality in COVID-19[J]. J Am Coll Cardiol, 2020, 76(1): 124-125.
[8] Nepal G, Rehrig J H, Shrestha G S, et al. Neurological manifestations of COVID-19: a systematic review[J]. Crit Care, 2020, 24(1): 421.
[9] Alqahtani S A, Schattenberg J M. Liver injury in COVID-19: the current evidence[J]. United European Gastroenterol J, 2020, 8(5): 509-519.
[10] Gabarre P, Dumas G, Dupont T, et al. Acute kidney injury in critically ill patients with COVID-19[J]. Intensive Care Med, 2020, 46(7): 1339-1348.
[11] Cheng Y C, Luo R, Wang K, et al. Kidney disease is associated with in-hospital death of patients with COVID-19[J]. Kidney Int, 2020, 97(5): 829-838.
[12] Pei G C, Zhang Z G, Peng J, et al. Renal involvement and early prognosis in patients with COVID-19 pneumonia[J]. J Am Soc Nephrol, 2020, 31(6): 1157-1165.
[13] Klok F A, Kruip M J H A, Van Der Meer N J M, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19[J]. Thromb Res, 2020, 191: 145-147.
[14] Magro C, Mulvey J J, Berlin D, et al. Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases[J]. Transl Res, 2020, 220: 1-13.
[15] Helms J, Tacquard C, Severac F, et al. High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study[J]. Intensive Care Med, 2020, 46(6): 1089-1098.
[16] Gupta A, Madhavan M V, Sehgal K, et al. Extrapulmonary manifestations of COVID-19[J]. Nat Med, 2020, 26(7): 1017-1032.
[17] Bertolini A, Van De Peppel I P, Bodewes F A J A, et al. Abnormal liver function tests in patients with COVID-19: relevance and potential pathogenesis[J]. Hepatology, 2020, 72(5): 1864-1872.
[18] Wang Y J, Liu S H, Liu H Y, et al. SARS-CoV-2 infection of the liver directly contributes to hepatic impairment in patients with COVID-19[J]. J Hepatol, 2020, 73(4): 807-816.
[19] Kucharski A J, Russell T W, Diamond C, et al. Early dynamics of transmission and control of COVID-19: a mathematical modelling study[J]. Lancet Infect Dis, 2020, 20(5): 553-558.
[20] Xu L, Liu J, Lu M J, et al. Liver injury during highly pathogenic human coronavirus infections[J]. Liver Int, 2020, 40(5): 998-1004.
[21] Chen N S, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study[J]. Lancet, 2020, 395(10223): 507-513.
[22] Cai Q X, Huang D L, Ou P C, et al. COVID-19 in a designated infectious diseases hospital outside Hubei Province, China[J]. Allergy, 2020, 75(7): 1742-1752.
[23] Cai Q X, Huang D L, Yu H, et al. COVID-19: abnormal liver function tests[J]. J Hepatol, 2020, 73(3): 566-574.
[24] Phipps M M, Barraza L H, LaSota E D, et al. Acute liver injury in COVID-19: prevalence and association with clinical outcomes in a large U.S. cohort[J]. Hepatology, 2020, 72(3): 807-817.